Weight loss drug contender Zealand Pharma jumps 18% on trial results
Publishing timestamp: 2024-06-21 11:43:20
Summary
Zealand Pharma shares rose after positive weight loss results from petrelintide, potentially offering better patient experience than current treatments like Novo Nordisk's Ozempic. Study showed up to 8.6% weight loss with minimal side effects, supporting potential as alternative to current therapies. Company plans to move to phase 2 trial.
Sentiment: POSITIVE
Tickers: LLY, ZEAL-DK, NOVO.B-DK,
Keywords: business news, breaking news: markets, zealand pharma a/s, novo nordisk a/s, eli lilly and co, pharmaceuticals, markets,